Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05514717 · ClinicalTrials.gov registry record · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
A Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer, sponsored by Mersana Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 162
- Enrollment target
- 14
- Study locations
NCT05514717: Recruiting Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer, sponsored by Mersana Therapeutics.
NCT05514717 is a Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer that is actively recruiting participants, run by Mersana Therapeutics. The registered enrollment target is 162 participants, below the 233-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (30% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05514717, a Phase 1 study of HER2-positive Breast Cancer and HER2-positive Gastric Cancer, is actively recruiting participants, sponsored by Mersana Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 162 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
Primary Outcome
Determine the maximum tolerated dose (MTD) of XMT-2056
Conditions Studied
Interventions
- DRUG XMT-2056
Study Locations (14)
California
- University of South California - Los Angeles
- University of California Los Angeles - Los Angeles
- Stanford University Medical Center - Stanford
New York
- New York University Medical Oncology Associates - New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- AdventHealth Celebration - Celebration
Georgia
- Emory Healthcare, Emory Clinic - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2023-01-24 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT05514717 shows while recruiting
NCT05514717 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 233-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (30% lower).
The record links to 6 conditions, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which XMT-2056 is the first listed.
NCT05514717 lists 14 locations in 10 states (California, New York, Florida).
Frequently Asked Questions
What is clinical trial NCT05514717 about?
NCT05514717 is a clinical study titled "A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2". A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
What is the current status of trial NCT05514717?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2023-01-24. Estimated completion is 2027-04.
What conditions does trial NCT05514717 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Low Breast Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer.
What interventions are being tested in trial NCT05514717?
The interventions under investigation include: XMT-2056 (DRUG).
Who is sponsoring clinical trial NCT05514717?
This trial is sponsored by Mersana Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05514717 being conducted?
This trial has 14 study locations across California, Florida, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05514717's enrollment target sits among peer trials
162 19th of 58 higher than 39 of 58 other HER2-positive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-positive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
HER-2 B Cell Peptide Vaccine
RECRUITING · Phase 1
-
HER2 Vaccine for Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05737693 · 162 participants · Phase 2
Enhancing Week-long Psychological Treatment for PTSD With Ketamine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI